IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?

Core Viewpoint - Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the commercialization of their products, with Iovance specializing in cancer immunotherapies and Rigel in hematologic disorders and cancer. The analysis aims to determine which company presents a better investment opportunity today. Summary of Iovance Biotherapeutics (IOVA) - Iovance has two marketed products: Proleukin for metastatic renal cell carcinoma and metastatic melanoma, and Amtagvi, the first FDA-approved individualized cell therapy for melanoma patients [2][3] - Amtagvi is expected to generate significant revenue, with projected sales of $155.1 million in the first nine months of 2025, reflecting a 183% year-over-year increase [3] - Total product revenues for Iovance are anticipated to be between $250 million and $300 million for the full year 2025, primarily driven by Amtagvi [4] - The company is exploring label expansions for Amtagvi in various cancer types, including cervical cancer and non-small cell lung cancer (NSCLC), with regulatory filings expected [5][6] - Iovance faced challenges in 2025, including a revenue guidance cut from $450-$475 million to $250-$300 million and the withdrawal of its EU filing for Amtagvi due to regulatory misalignment [7] Summary of Rigel Pharmaceuticals (RIGL) - Rigel has shown strong performance in 2025, with sales rising 60% to $232 million, primarily driven by Tavalisse, which generated nearly $159 million [8][10][11] - Tavalisse is approved for treating adults with low platelet counts due to chronic immune thrombocytopenia, and its strong demand has reinforced Rigel's revenue base [9][11] - Rigel's oncology assets, including Gavreto and Rezlidhia, contributed additional revenue, with Gavreto generating about $42 million and Rezlidhia $31 million [12] - The company projects 2026 net product sales of $255-$265 million and expects to achieve positive net income while funding clinical development programs [13] - Rigel faces competition from larger pharmaceutical companies, notably Sanofi's Wayrilz, which poses a threat to Tavalisse [15] Financial Estimates and Performance - The Zacks Consensus Estimate for IOVA's 2026 sales is expected to grow by over 81%, with loss estimates per share improving by 34% [17] - For Rigel, the 2026 sales estimate is expected to decline by 3%, with EPS estimates dropping by about 41% [18] - In the past year, IOVA shares have decreased by 46%, while RIGL shares have increased by 59%, contrasting with an industry growth of nearly 18% [19] - Iovance is trading at a premium with a price/sales ratio of 4.20, compared to Rigel's 2.33 [21] Investment Considerations - Both companies hold a Zacks Rank 3 (Hold), complicating the investment decision [23] - Iovance is viewed as a safer investment due to its growth potential from Amtagvi and ongoing pipeline programs, despite its premium valuation [24] - Rigel, while operationally stronger in the short term, has a more concentrated portfolio and faces increasing competition [24] - Iovance's past setbacks are seen as temporary, with potential for greater upside if commercialization trends stabilize [25]